
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio is supported by compelling prula-cel data in lupus nephritis and systemic lupus erythematosus, where 50% of evaluable LN patients achieved complete renal response at 12 months and 54% reached DORIS remission, with responses ongoing through 12 to 21 months and all patients discontinuing immunosuppressants. Its safety profile also appears differentiated, with no CRS above Grade 2, no ICANS, no IEC-HS, and only 8.3% Grade 3 or higher infections, reinforcing the appeal of an off-the-shelf, outpatient-friendly allogeneic platform. The outlook is further strengthened by pivotal study start-up next quarter, a planned FDA meeting in 4Q26 on expanding into lupus without nephritis, and ADI-212 receiving IND clearance and Fast Track designation, all of which enhance the 2027 catalyst set.
Bears say
Adicet Bio is viewed negatively because it remains a pre-revenue clinical-stage biotech with no proven commercial engine, yet it posted a net loss of $18.9MM, or ($1.76) per share, alongside $15.6MM of R&D expense and $4.2MM of G&A expense. Although it ended the quarter with approximately $100.9MM in cash and expects runway into 2H27, the business still faces material financing risk until it becomes cash flow positive, while clinical and regulatory failure of ADI-001, delayed trial initiation, or unexpected safety issues could materially impair value. The outlook is further pressured by management’s removal of SSc from valuation and the continued dependence on unproven programs like prula-cel and ADI-212, which leaves execution, competition, and commercialization risks unresolved.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Adicet Bio, Inc. (ACET) Forecast
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares